André Kobelt
Chief Executive Officer at Heraeus Deutschland GmbH & Co. KG
Profile
André Kobelt is currently the Co-Managing Director at Heraeus Deutschland GmbH & Co. KG, the Director at mimiX Biotherapeutics Ltd., and the Chief Operating Officer at Heraeus Holding GmbH.
André Kobelt active positions
Companies | Position | Start |
---|---|---|
Heraeus Deutschland GmbH & Co. KG
Heraeus Deutschland GmbH & Co. KG Other Metals/MineralsNon-Energy Minerals Heraeus Deutschland GmbH & Co. KG engages in the development and production of materials for the assembly and packaging of devices in the electronics industry. It offers material solutions for consumer electronics, information technology, automotive, power electronics, and communications sectors. The firm specializes in bonding wires, adhesives, solder materials, sinter materials, thick film pastes, as well as metal and metal ceramic substrates. The company was founded by Wilhelm Carl Heraeus in 1851 and is headquartered in Hanau, Germany. | Chief Executive Officer | - |
Heraeus Holding GmbH
Heraeus Holding GmbH Wholesale DistributorsDistribution Services Heraeus Holding GmbH operates as a technology company. It focuses on the environmental, energy, electronics, health, mobility and industrial applications sectors. The company was founded by Willhelm Carl Heraeus in 1851 and is headquartered in Hanau, Germany. | Chief Operating Officer | 2015-12-31 |
Mimix Biotherapeutics Sàrl
Mimix Biotherapeutics Sàrl BiotechnologyHealth Technology Mimix Biotherapeutics Sàrl is a private company located in Switzerland that develops and commercializes a platform to overcome limitations in tissue engineering, specifically the vascularization challenge and the need for high cell quantities. The Swiss company creates biological architectures with sound using sound-induced morphogenesis, which is a gentle, fast, and easy method to generate multi-cellular, spatially orchestrated tissue constructs using sound waves. The company offers guides for patterning parameters and cells in various hydrogels, including collagen, fibrin, gelatine, and synthetic hydrogels. The company's FastSkin® technology combines micrografting with sound-induced morphogenesis to improve wound care management, addressing a major social burden and unmet clinical need in oncology and chronic wounds treatments. Mimix Biotherapeutics also provides control over cellular and extracellular organization at high spatial resolution to investigate cell-material interactions in vitro models. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Heraeus Holding GmbH
Heraeus Holding GmbH Wholesale DistributorsDistribution Services Heraeus Holding GmbH operates as a technology company. It focuses on the environmental, energy, electronics, health, mobility and industrial applications sectors. The company was founded by Willhelm Carl Heraeus in 1851 and is headquartered in Hanau, Germany. | Distribution Services |
Heraeus Deutschland GmbH & Co. KG
Heraeus Deutschland GmbH & Co. KG Other Metals/MineralsNon-Energy Minerals Heraeus Deutschland GmbH & Co. KG engages in the development and production of materials for the assembly and packaging of devices in the electronics industry. It offers material solutions for consumer electronics, information technology, automotive, power electronics, and communications sectors. The firm specializes in bonding wires, adhesives, solder materials, sinter materials, thick film pastes, as well as metal and metal ceramic substrates. The company was founded by Wilhelm Carl Heraeus in 1851 and is headquartered in Hanau, Germany. | Non-Energy Minerals |
Mimix Biotherapeutics Sàrl
Mimix Biotherapeutics Sàrl BiotechnologyHealth Technology Mimix Biotherapeutics Sàrl is a private company located in Switzerland that develops and commercializes a platform to overcome limitations in tissue engineering, specifically the vascularization challenge and the need for high cell quantities. The Swiss company creates biological architectures with sound using sound-induced morphogenesis, which is a gentle, fast, and easy method to generate multi-cellular, spatially orchestrated tissue constructs using sound waves. The company offers guides for patterning parameters and cells in various hydrogels, including collagen, fibrin, gelatine, and synthetic hydrogels. The company's FastSkin® technology combines micrografting with sound-induced morphogenesis to improve wound care management, addressing a major social burden and unmet clinical need in oncology and chronic wounds treatments. Mimix Biotherapeutics also provides control over cellular and extracellular organization at high spatial resolution to investigate cell-material interactions in vitro models. | Health Technology |
- Stock Market
- Insiders
- André Kobelt